%0 Journal Article
%T Daptomycin dosing in obese patients: analysis of the use of adjusted body weight versus actual body weight
%A Ashley N. Fox
%A Beth H. Resman-Targoff
%A Bryan P. White
%A Katherine E. Kupiec
%A Ryan E. Owens
%A Stephanie J. Harding
%A Stephen B. Neely
%A Winter J. Smith
%J Archive of "Therapeutic Advances in Infectious Disease".
%D 2019
%R 10.1177/2049936118820230
%X Food and Drug Administration¨Capproved daptomycin dosing uses actual body weight, despite limited dosing information for obese patients. Studies report alterations in daptomycin pharmacokinetics and creatine phosphokinase elevations associated with higher weight-based doses required for obese patients. Limited information regarding clinical outcomes with alternative daptomycin dosing strategies in obesity exists
%K creatine phosphokinase
%K daptomycin
%K dosing
%K obesity
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354309/